Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics reported its provisional Q2 2024 consolidated financial results, recording revenue of approximately KRW 1.157T and operating profit of KRW 434.5B, up 33.56% and 71.45% year-over-year, respectively.
📊 [Key Disclosure Details & Summary Statistics]
(Unit: KRW Million)
- Q2 2024 Standalone Period Performance (3 Months):
- Revenue: KRW 1,156,904M (KRW ~1.157T) (+22.18% QoQ, +33.56% YoY)
- Operating Profit: KRW 434,511M (KRW ~434.5B) (+96.35% QoQ, +71.45% YoY)
- Profit Before Income Tax: KRW 464,960M (+93.67% QoQ, +85.01% YoY)
- Net Profit: KRW 317,992M (+77.29% QoQ, +71.99% YoY)
- Net Profit Attributable to Owners of Parent: KRW 317,992M (+77.29% QoQ, +71.99% YoY)
- Q2 2024 Cumulative Performance (6 Months):
- Revenue: KRW 2,103,808M (KRW ~2.104T) (+32.56% YoY)
- Operating Profit: KRW 655,810M (KRW ~655.8B) (+47.31% YoY)
- Profit Before Income Tax: KRW 705,037M (+57.39% YoY)
- Net Profit: KRW 497,354M (+52.26% YoY)
- Net Profit Attributable to Owners of Parent: KRW 497,354M (+52.26% YoY)
- Other Key Investment Matters:
- The figures provided above are preliminary metrics prepared prior to the completion of the external audit and are subject to change based on audit results.
- Related earnings presentation materials will be posted on the official company website (http://www.samsungbiologics.com).
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Variance Between Provisional and Final Audit Figures
This disclosure reflects preliminary financial results published prior to the completion of an external audit. Comparing these provisional figures with the audited financial statements in the upcoming half-year report to check for any discrepancies between preliminary and final figures is important for understanding the confirmed financial results for the period. Detailed financial statements can be verified through upcoming periodic filings, such as the half-year report.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided strictly for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
